Legal & General Group
OMIC

Legal & General Group’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Legal & General Group’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-206
Closed -$7.47K – 3551
2023
Q1 		$7.47K Hold
206
– – ﹤0.01% 3250
2022
Q4 		$12.4K Buy
206
+49
+31% +$3.28K ﹤0.01% 3234
2022
Q3 		$12K Hold
157
– – ﹤0.01% 3314
2022
Q2 		$18K Buy
157
+7
+5% +$821 ﹤0.01% 3283
2022
Q1 		$28K Buy
150
+113
+305% +$26.1K ﹤0.01% 3149
2021
Q4 		$13K Hold
37
– – ﹤0.01% 3416
2021
Q3 		$12K Buy
37
+20
+118% +$10.3K ﹤0.01% 3425
2021
Q2 		$14K Buy
+17
New +$13.2K ﹤0.01% 3392

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group's OMIC Position: Q2 2023 in Review

Legal & General Group sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q2 2023, closing a stake of 206 shares — an estimated $7.47K sold.

Legal & General Group first reported a position in OMIC in Q2 2021 and held it in 8 quarters. The position peaked at $28K in Q1 2022. 62 funds tracked by Wall St. Rank hold OMIC as of Q2 2023.

  • Legal & General Group reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Legal & General Group sold 206 Singular Genomics Systems, Inc. Common Stock shares in Q2 2023, an estimated $7.47K.
  • Legal & General Group first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • Legal & General Group's Singular Genomics Systems, Inc. Common Stock position peaked at $28K in Q1 2022.
  • 62 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.